Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Non–Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial
- 31 October 2008
- journal article
- research article
- Published by Elsevier BV in International Journal of Radiation Oncology*Biology*Physics
- Vol. 73 (4), 1069-1076
- https://doi.org/10.1016/j.ijrobp.2008.05.068
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Oncologic Emergencies: Diagnosis and TreatmentMayo Clinic Proceedings, 2006
- Motexafin Gadolinium, a Tumor-selective Drug Targeting Thioredoxin Reductase and Ribonucleotide ReductaseJournal of Biological Chemistry, 2006
- Motexafin Gadolinium and Zinc Induce Oxidative Stress Responses and Apoptosis in B-Cell Lymphoma LinesCancer Research, 2005
- Current Management of Brain Metastases, With a Focus on Systemic OptionsJournal of Clinical Oncology, 2005
- Motexafin Gadolinium Disrupts Zinc Metabolism in Human Cancer Cell LinesCancer Research, 2005
- Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2004
- Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain MetastasesJournal of Clinical Oncology, 2003
- Phases IB and II Multidose Trial of Gadolinium Texaphyrin, a Radiation Sensitizer Detectable at MR Imaging: Preliminary Results in Brain MetastasesRadiology, 1999
- Properties of the urn randomization in clinical trialsControlled Clinical Trials, 1988
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958